CHEMOPREVENTION CLINICAL-TRIALS
CHEMOPREVENTION CLINICAL-TRIALS
复制标题
DOI：
10.1016/0027-5107(92)90073-b
复制
发表时间：
1992-06-01
期刊：
影响因子：
--
通讯作者：
STEELE, VE
中科院分区：
文献类型：
--
作者：
KELLOFF, GJ;BOONE, CW;STEELE, VE
作为开发延缓或预防人类癌症的药物计划的一部分，美国国立卫生研究院国家癌症研究所化学预防分部将赞助12项I期临床试验和22项II期和III期临床试验。有三类药物在试验中取得了显著的进步。这些是维甲酸，包括13-顺式维甲酸、视黄醇和4-羟基苯基视黄胺(9项研究)、β-胡萝卜素(7项研究)和钙化合物(3项研究)。此外，6种有希望的新化合物正在进行第一阶段或第二阶段的试验。它们是：吡罗昔康、布洛芬、奥替拉兹(一种二硫代硫酮)、二氟甲基鸟氨酸、甘草次酸和N-乙酰半胱氨酸。与开发癌症化学预防药物有关的关键概念是(1)长期给药的必要性，(2)口服给药途径的必要性，(3)毒副作用与癌症风险程度的匹配。
As part of a program to develop drugs which will delay or prevent cancer in humans, the Chemoprevention Branch, National Cancer Institute, National Institutes of Health, is sponsoring 12 Phase I and 22 Phase II and III clinical trials. Three agent classes are significantly advanced in the trials. These are the retinoids, including 13-cis-retinoic acid, retinol, and 4-hydroxyphenylretinamide (nine studies), beta-carotene (seven studies), and calcium compounds (three studies). In addition, six promising new compounds are in Phase I or Phase II trials. These are: piroxicam, ibuprofen, oltipraz (a dithiolthione), difluoromethylornithine, glycyrrhetinic acid, and N-acetylcysteine. Key concepts related to the development of cancer chemopreventive agents are (1) the need for long-term administration, (2) the need for oral route of administration, (3) the matching of toxic side effects to degree of cancer risk.